This website has been developed by Besins Healthcare (UK) Ltd.
This website has separate sections for healthcare professionals (containing promotional information), and patients who have been prescribed Testogel® (testosterone) 16.2 mg/g gel, within the UK.
Please confirm that:
A prostate-specific antigen (PSA) test and digital rectal examination (DRE) is recommended.
It’s important to check if the patient has any of the following contraindications:
When prescribing Testogel® 16.2 mg/g gel, treatment should only be started in adults as testosterone replacement therapy for male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests.2 A number of clinical tools, in addition to clinical guidelines, are available to help you decide when to treat patients.
TES/2020/009. April 2021.
Adverse event reporting
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: firstname.lastname@example.org
Stay informed about the latest safety information and warnings associated with Testogel® 16.2 mg/g gel.